Mantle cell lymphoma treatment offers options if patients relapse after CAR T-cell therapy, from bispecific antibodies, antibody drug conjugates, and other emerging therapies.

During a live event, Matthew Lunning, DO, and participants discussed how identifying primary refractory and early relapsed ...

Treatment options for patients with moderately to severely active Crohn's disease have expanded in the past decade, with ...

The patients receiving AHSCT had 5-year LFS of 46.3% and OS of 53.3%, which were better outcomes than those of the MRC UKALL XII/ECOG E2993 trial conducted from 2006 to 2010.